id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-N-2673-0001,FDA,FDA-2022-N-2673,Safety and Effectiveness of Certain Naloxone Hydrochloride Drug Products for Nonprescription Use; Request for Comments,Notice,Request for Comments,2022-11-16T05:00:00Z,2022,11,2022-11-16T05:00:00Z,2023-01-18T04:59:59Z,2023-01-19T02:00:34Z,2022-24874,0,0,09000064854bb10e